Oxford BioTherapeutics To Collaborate With Seattle Genetics On ADCs
This article was originally published in The Pink Sheet Daily
Executive Summary
In tandem with Seattle Genetics, Oxford BioTherapeutics hopes to take a monoclonal antibody product for cancer into the clinic next year.